Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 3.342
Filtrar
1.
Clin Nurse Spec ; 34(2): 45-47, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32068631

RESUMO

Recently, there seems to be more creative advertising regarding bismuth subsalicylate (BSS) for lots of gastrointestinal issues. I have found during medication reconciliation that some patients overuse and believe use of BSS products is without risks. From an advertising perspective, there seem to be many happy persons consuming BSS with no mention of restrictions or safety recommendations. What are the risks associated with its use? How effective is BSS? What about drug interactions?


Assuntos
Bismuto/uso terapêutico , Compostos Organometálicos/uso terapêutico , Salicilatos/uso terapêutico , Bismuto/efeitos adversos , Medicina de Família e Comunidade , Humanos , Enfermeiras Clínicas , Compostos Organometálicos/efeitos adversos , Salicilatos/efeitos adversos
2.
Cancer Sci ; 111(3): 924-931, 2020 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-31943636

RESUMO

The formation of premetastatic niches creates a fertile environment for the seeding of disseminated cancer cells in selected secondary organs. This is crucial for the development of metastasis in various malignancies, including breast cancer (BC). We previously reported that the loss of FBXW7 in bone marrow-derived stromal cells promoted cancer metastasis by increasing the production of the chemokine CCL2, which attracts myeloid-derived suppressor cells and macrophages to the premetastatic niche. Furthermore, treatment with the CCL2 inhibitor propagermanium (PG), which has been used in Japan as a therapeutic agent against chronic hepatitis B, was shown to block the enhancement of metastasis in FBXW7-deficient mice through inhibiting the formation of premetastatic niches. Here, we describe a phase I dose-escalation study of PG used as an antimetastatic drug for perioperative patients with primary BC. The primary end-point was the percentage of patients who experience dose-limiting toxicity. Twelve patients were enrolled in the study. Dose-limiting toxicity was not observed, and the maximum dose was determined to be 90 mg/body/day. The serum concentrations of PG were nearly within the normal range in all observation days. We observed an inverse correlation between FBXW7 mRNA levels in blood and the serum concentrations of CCL2 and interleukin (IL)-6, in agreement with our previous mouse model. Also, IL-6 was downregulated in a PG dose-dependent manner, as observed in mice. Thus, PG was given safely and it is expected to have antimetastatic potential in BC. This trial is registered in the UMIN Clinical Trials Registry as UMIN000022494.


Assuntos
Antineoplásicos/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Quimiocina CCL2/antagonistas & inibidores , Compostos Organometálicos/uso terapêutico , Adulto , Idoso , Neoplasias da Mama/genética , Proteína 7 com Repetições F-Box-WD/genética , Feminino , Humanos , Interleucina-6/genética , Japão , Macrófagos/efeitos dos fármacos , Pessoa de Meia-Idade , Células Supressoras Mieloides/efeitos dos fármacos , RNA Mensageiro/genética , Transdução de Sinais/genética , Adulto Jovem
3.
Chemistry ; 26(8): 1697, 2020 Feb 06.
Artigo em Inglês | MEDLINE | ID: mdl-31922634

RESUMO

Invited for the cover of this issue is the group of Torres at the University of Madrid. The image of the cover of this issue depicts cancer cells being destroyed by reactive singlet oxygen produced by ruthenium phthalocyanine glycoconjugates under red light. The work, developed at the Universities of Madrid, Aveiro, Lisbon and Coimbra, describes ruthenium phthalocyanines as powerful bladder cancer PDT agents. Read the full text of the article at 10.1002/chem.201903546.


Assuntos
Compostos Organometálicos/química , Fármacos Fotossensibilizantes/química , Oxigênio Singlete/metabolismo , Humanos , Compostos Organometálicos/síntese química , Compostos Organometálicos/uso terapêutico , Fotoquimioterapia , Fármacos Fotossensibilizantes/síntese química , Fármacos Fotossensibilizantes/uso terapêutico , Neoplasias da Bexiga Urinária/tratamento farmacológico
4.
Anticancer Res ; 39(12): 6693-6699, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31810934

RESUMO

BACKGROUND/AIM: Melanoma represents a big challenge for clinical treatment. Besides being the most aggressive and the deadliest form of skin cancer, it is often refractory to commonly used anticancer drugs. Hence, developing new anti-cancer agents is crucial to improve refractory melanoma treatment. Studies using palladium(II) complexes have reported antitumor effects on cancer cells. In this study, we aimed to determine the cytotoxic effect of three novel synthesized Pd(II) complexes with Schiff bases derived from 4-aminoacetophenone on the MDA-MB-435 melanoma cell line. MATERIALS AND METHODS: Cells were treated with ligand and Pd(II) complexes. Cell viability, morphology and death induction upon treatment were examined. RESULTS: Novel synthesized Pd(II) complexes led to decreased viability of cells. They also induced morphological alterations and cell death, mainly in the C3 complex. CONCLUSION: The novel synthesized complexes have a significant cytotoxic effect on cell line MDA-MB-435, especially C3 and can be considered as an antitumor agent for further studies.


Assuntos
Acetofenonas/química , Antineoplásicos/uso terapêutico , Melanoma/tratamento farmacológico , Compostos Organometálicos/uso terapêutico , Paládio/uso terapêutico , Bases de Schiff/uso terapêutico , Neoplasias Cutâneas/tratamento farmacológico , Antineoplásicos/síntese química , Morte Celular , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Ensaios de Seleção de Medicamentos Antitumorais , Humanos , Técnicas In Vitro , Ligantes , Compostos Organometálicos/síntese química , Paládio/química , Rodaminas , Bases de Schiff/química
5.
Medicine (Baltimore) ; 98(52): e18478, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31876733

RESUMO

RATIONALE: Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs is a targeted internal radiotherapy method used to treat tumors expressing somatostatin receptors. Concomitant amino acids perfusion is systematically performed in order to inhibit the proximal tubular uptake of the radionuclide and thus prevent nephrotoxicity. PATIENT CONCERNS:: a 67-year-old woman with an intestinal neuroendocrine tumor with multiple lymphadenopathies and liver metastases. The patient displayed a carcinoid syndrome with flushes including facial erythrosis and paresthesia. During the treatment, the patient exhibited emesis and severe cramps. DIAGNOSIS: We describe incomplete proximal tubulopathy induced by an amino acid therapy with [177Lu]-DOTA0-Tyr3-octreotate, which was reversible after treatment discontinuation. This diagnosis relies on metabolic acidosis, hypophosphatemia due to renal loss, tubular proteinuria and generalized aminoaciduria. Serum creatinine remained stable during and after the procedure. INTERVENTIONS: PRRT with radiolabeled somatostatin analog ([177Lu]-DOTA0-Tyr3-octreotate). In order to prevent PRRT induced nephrotoxicity, we used a solution of 20 amino acids including 22 g/L Lysine and 16.8 g/L Arginine. Metoclopramide was successfully used to control vomiting. During the treatment and at the time of cramps, the blood sample showed hypophosphatemia at 0.3 mmol/L justifying intravenous phosphate supplementation. The cramps disappeared after this infusion. OUTCOMES: Hypophosphatemia with low TmPO4/GFR was observed as well as an increase in ß2-microglobulinuria, urinary polyclonal light chains, and amino aciduria involving all amino acids. All these disturbances disappeared the day after the treatment and there was no acute kidney injury after 5 PRRT sessions. Six months after PRRT discontinuation, the patient had neither renal failure nor proximal tubulopathy. Aminoacid induced tubulopathy involves the main ligands of the megalin receptor. It has recently been demonstrated that cilastatin is a megalin inhibitor in the proximal tubule and therefore could represent an attractive alternative to amino acids for this purpose. LESSONS: This case report is a description of a nephroprotective strategy in which partial, and transient tubulopathy is induced, in order to decrease proximal absorption of a tubulotoxic molecule. This little known strategy could be used to prevent proximal tubular injury caused by others megalin-mediated nephrotoxicity medication.


Assuntos
Aminoácidos/efeitos adversos , Síndrome de Fanconi/induzido quimicamente , Octreotida/análogos & derivados , Compostos Organometálicos/efeitos adversos , Idoso , Aminoácidos/administração & dosagem , Feminino , Humanos , Neoplasias Intestinais/radioterapia , Túbulos Renais Proximais/efeitos dos fármacos , Tumores Neuroendócrinos/radioterapia , Octreotida/efeitos adversos , Octreotida/uso terapêutico , Compostos Organometálicos/uso terapêutico , Radioisótopos/efeitos adversos , Radioisótopos/uso terapêutico , Receptores de Peptídeos
7.
Chemotherapy ; 64(3): 163-166, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31655804

RESUMO

Carbohydrate antigen 19-9 (CA 19-9) is a well-known tumor marker of adenocarcinoma (reference range, 37 U/mL). It can also be used, together with computed tomography, to monitor responses and resistance to chemotherapy in cancer patients. False elevation of CA 19-9 levels is often seen in conditions such as biliary tract obstruction and cholangitis. However, whether medication might induce false elevation of CA 19-9 levels has not yet been reported. A 74-year-old man was treated with third-line CPT-11 (irinotecan) plus panitumumab for stage IV cancer of the ascending colon. The patient developed chemotherapy-induced dysgeusia and was treated with polaprezinc. After polaprezinc administration, his CA 19-9 levels gradually increased from 18.9 to 1,699.4 U/mL. He developed deep vein thrombosis (DVT), although it was not associated with progressive disease or metastasis. Upon discontinuation of polaprezinc, CA 19-9 levels gradually decreased. This case demonstrates that polaprezinc may not only induce false elevation of CA 19-9 levels but also cause development of DVT induced by increased CA 19-9 levels, both of which are very rare events.


Assuntos
Antígeno CA-19-9/metabolismo , Carnosina/análogos & derivados , Neoplasias do Colo/patologia , Disgeusia/tratamento farmacológico , Compostos Organometálicos/uso terapêutico , Trombose Venosa/diagnóstico , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carnosina/efeitos adversos , Carnosina/uso terapêutico , Neoplasias do Colo/tratamento farmacológico , Disgeusia/complicações , Disgeusia/diagnóstico , Veia Femoral , Humanos , Masculino , Compostos Organometálicos/efeitos adversos , Tomografia Computadorizada por Raios X , Trombose Venosa/etiologia , Compostos de Zinco/efeitos adversos , Compostos de Zinco/uso terapêutico
8.
Photodiagnosis Photodyn Ther ; 27: 402-407, 2019 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-31284075

RESUMO

BACKGROUND: Antimicrobial photodynamic therapy (aPDT) has been considered an alternative therapeutic modality for the treatment of Candida infections. However, most studies are focused mainly on microorganism's inactivation efficiency. Here, we evaluated the efficacy of aPDT mediated by chloro-aluminum phthalocyanine encapsulated in cationic nanoemulsions (ClAlP-NE) to treat oral candidiasis in vivo and its effect on the adhesion and biofilm formation of Candida albicans. METHODS: For this, mice were immunosuppressed and inoculated with C. albicans to produce oral candidiasis. aPDT and Nystatin were applied for 5 successive sessions. Next, the microbiological evaluation was determined (CFU/ml) and the analyses of virulence factors (adhesion capacity and biofilm formation) were performed. Data were analyzed by Two-way ANOVA (α = 0.05). RESULTS: aPDT was as effective as Nystatin reducing 1.4 and 2.0 log10 of the cell viability (p ≤ 0.0001), respectively. Both treatments reduced the adhesion capacity and biofilm formation of C. albicans (p ≤ 0.0001) CONCLUSION: : ClAlP-NE-mediated aPDT was effective in reducing the virulence factors of C. albicans and also to treat induced oral candidiasis in mice.


Assuntos
Biofilmes/efeitos dos fármacos , Candidíase Bucal/tratamento farmacológico , Indóis/uso terapêutico , Compostos Organometálicos/uso terapêutico , Fotoquimioterapia/métodos , Fármacos Fotossensibilizantes/uso terapêutico , Animais , Antifúngicos/uso terapêutico , Candida albicans/efeitos dos fármacos , Emulsões , Indóis/administração & dosagem , Camundongos , Nanopartículas , Nistatina/uso terapêutico , Compostos Organometálicos/administração & dosagem
9.
Clin Nucl Med ; 44(8): 650-652, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-31274613

RESUMO

A 77-year-old man with a history of metastatic Merkel cell carcinoma and debilitating painful cutaneous lesions was referred to our nuclear medicine department for peptide receptor radionuclide therapy with Lu-DOTATATE as ultimate therapeutic option. Post-treatment whole body scan showed multiple zones of Lu-DOTATATE uptake in the metastatic regions, which revealed significant improvement within the next 10 days of therapy. Peptide receptor radionuclide therapy in metastatic Merkel cell carcinoma is an effective therapeutic option that should be considered in earlier stages of the disease.


Assuntos
Carcinoma de Célula de Merkel/radioterapia , Tumores Neuroendócrinos/radioterapia , Idoso , Carcinoma de Célula de Merkel/diagnóstico por imagem , Carcinoma de Célula de Merkel/patologia , Humanos , Masculino , Metástase Neoplásica , Tumores Neuroendócrinos/diagnóstico por imagem , Tumores Neuroendócrinos/patologia , Octreotida/análogos & derivados , Octreotida/uso terapêutico , Compostos Organometálicos/uso terapêutico , Compostos de Organotecnécio , Tomografia por Emissão de Pósitrons , Compostos Radiofarmacêuticos/uso terapêutico , Imagem Corporal Total
10.
Trop Anim Health Prod ; 51(8): 2379-2386, 2019 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-31177472

RESUMO

The effect of multinutrient antioxidant treatment on sheep naturally infected with FMD virus was investigated in terms of general health conditions, serum proteins profile, and antioxidant/oxidant parameters. Twenty diseased sheep were divided into 4 equal groups (n = 5) and underwent certain therapeutic protocols for 8 weeks as follows: GI, infected not treated group; GII, infected and treated with the ideal and usual line of treatment against FMD virus infection; GIII, infected animals supplemented orally zinc methionine at a dose of 5 g/head/day and vitamin E with selenium-enriched yeast at the same dose level; GIV, infected animals received both the ideal treatment and antioxidants. The animals under experiment were clinically evaluated. Blood samples were obtained for the comet assay and biochemical examination at zero time and at the 8th week after treatment. Results revealed that DNA damage reduced in both GIII and GIV groups which received antioxidants. In the GI group, the activity of SOD and GPx and the level of total antioxidant capacity (TAC) markedly decreased. However, in both GIII and GIV groups treated with multinutrient antioxidants, GPx and TAC values significantly increased after treatment in comparison with the values of the same groups before treatment. After treatment with multinutrient antioxidants, α1-, ß-, and γ-globulins levels markedly increased in GII and GIII groups while α2-globulin level decreased. The improvement in healing of clinical signs and general health conditions was clear in the GIV group. Finally, FMD infection in sheep was found to be associated with oxidative stress. The use of antioxidants as therapeutic approaches recovers and improves general health conditions and performance of affected animals.


Assuntos
Antioxidantes/uso terapêutico , Febre Aftosa/tratamento farmacológico , Estresse Oxidativo/efeitos dos fármacos , Doenças dos Ovinos/tratamento farmacológico , Animais , Antioxidantes/metabolismo , Antioxidantes/farmacologia , Proteínas Sanguíneas/metabolismo , Metionina/análogos & derivados , Metionina/uso terapêutico , Compostos Organometálicos/uso terapêutico , Selênio/uso terapêutico , Ovinos , Vitamina E/uso terapêutico
11.
Cardiovasc Intervent Radiol ; 42(11): 1649-1652, 2019 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-31187231

RESUMO

Somatostatin receptor subtype 2 upregulation is very common in meningiomas, and the use of peptide receptor radionuclide therapy (PRRT) is recognized in recent European guidelines, with long-term stable disease and a long overall survival. Treatment efficacy of radionuclide treatments is correlated with tumour radiation absorbed dose. Meningioma patients with low tumour uptake might benefit less from treatment. Thus, a method to increase tumour uptake in these patients is needed. We describe a case treated with both intravenous and intra-arterial PRRT. Tumour uptake after intravenous PRRT was disappointing, and after intra-arterial administration significantly increased tumour uptake was seen. Patient had a partial response on imaging and reduction in tumour-related complaints. Potentially, intra-arterial administration of PRRT could increase treatment efficacy in meningioma patients.Level of Evidence 5 (case report).


Assuntos
Neoplasias Meníngeas/radioterapia , Meningioma/radioterapia , Octreotida/análogos & derivados , Compostos Organometálicos/uso terapêutico , Receptores de Somatostatina/efeitos da radiação , Terapia de Salvação/métodos , Feminino , Humanos , Infusões Intra-Arteriais , Pessoa de Meia-Idade , Tumores Neuroendócrinos/patologia , Octreotida/administração & dosagem , Octreotida/uso terapêutico , Compostos Organometálicos/administração & dosagem , Resultado do Tratamento
14.
Drug Des Devel Ther ; 13: 1409-1420, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31118576

RESUMO

Background: This study aimed to design a compound with folic acid (FAH2) and vanadyl (IV) for use in the treatment of diabetes. Materials and methods: A novel vanadyl (IV) FAH2 complex was synthesized and characterized [(FA2-)(VO2+)]⋅3H2O. The speculated structure of this folate complex was determined using physicochemical techniques including microanalytical analysis, conductivity studies, spectroscopic examination, magnetic measurements, thermogravimetric analyses, and morphological X-ray powder diffraction, and scanning and transmission electron microscopies. The anti-diabetic therapeutic potential of the complexes was tested in a 30-day streptozotocin-induced diabetes rat model. Results: The conductivity test of the complex implied electrolyte behavior. The spectroscopic assessments of the isolated dark yellow solid complex revealed that FAH2 acts as a bidentate ligand. The coordination process with two vanadyl (IV) ions occurred through the deprotonation of both carboxyl groups of FAH2 in a regular square pyramid arrangement at a 2(FA)2-: 2(VO)2+ molar ratio. XRD, SEM, and TEM analyses revealed the complex crystalline nature of the complex. Treating diabetic rats with vanadyl (IV) FAH2 complex significantly improved many biological parameters relevant to diabetes pathology with minimal toxicity. Conclusion: The data generated in this study indicate that the synthesized vanadyl (IV) folate complex acts as a model of anti-diabetic agent.


Assuntos
Diabetes Mellitus Experimental/tratamento farmacológico , Ácido Fólico/química , Hipoglicemiantes/química , Hipoglicemiantes/síntese química , Compostos Organometálicos/síntese química , Vanadatos/química , Animais , Diabetes Mellitus Experimental/induzido quimicamente , Diabetes Mellitus Experimental/patologia , Espectroscopia de Ressonância de Spin Eletrônica , Ácido Fólico/uso terapêutico , Hipoglicemiantes/uso terapêutico , Masculino , Estrutura Molecular , Compostos Organometálicos/química , Compostos Organometálicos/uso terapêutico , Tamanho da Partícula , Ratos , Espectrofotometria Infravermelho , Estreptozocina , Propriedades de Superfície , Termodinâmica , Vanadatos/uso terapêutico
15.
Cancer Sci ; 110(7): 2090-2099, 2019 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-31111571

RESUMO

Inflammation plays an essential role in the development and progression of most cancers. Chemokine C-C motif chemokine 2 (CCL2) and its receptor C-C chemokine receptor type 2 (CCR2) constitute a key signaling axis in inflammation that has recently attracted much interest on the basis of evidence showing its association with cancer progression. Propagermanium (3-oxygermylpropionic acid polymer) is an organogermanium compound that is given for the treatment of hepatitis B in Japan and which inhibits the CCL2-CCR2 signaling pathway. Herein, we review the importance of the CCL2-CCR2 axis as a target in cancer treatment as shown by studies in mice and humans with pharmacological agents including propagermanium.


Assuntos
Antineoplásicos/farmacologia , Quimiocina CCL2/metabolismo , Neoplasias/tratamento farmacológico , Compostos Organometálicos/farmacologia , Receptores CCR2/metabolismo , Animais , Antineoplásicos/metabolismo , Antineoplásicos/uso terapêutico , Ensaios Clínicos como Assunto , Humanos , Japão , Camundongos , Neoplasias/imunologia , Compostos Organometálicos/química , Compostos Organometálicos/uso terapêutico , Transdução de Sinais/efeitos dos fármacos , Bibliotecas de Moléculas Pequenas/farmacologia , Bibliotecas de Moléculas Pequenas/uso terapêutico
16.
AJR Am J Roentgenol ; 213(2): 309-317, 2019 08.
Artigo em Inglês | MEDLINE | ID: mdl-31039017

RESUMO

OBJECTIVE. The purpose of this article is to enhance knowledge of the clinical implementation of peptide receptor radionuclide therapy (PRRT) and its impact on care of patients with neuroendocrine tumors. CONCLUSION. Most well differentiated and some moderately and poorly differentiated neuroendocrine tumors express large numbers of somatostatin receptors on their cell surfaces. PRRT targets these cells with 177Lu-DOTATATE, which is a medium-energy beta emitter. Since this agent received U.S. Food and Drug Administration approval in 2018, tremendous effort has been exerted at institutions throughout the United States toward proper implementation of this promising therapy. This review summarizes clinical implementation of PRRT and its impact on patient care.


Assuntos
Tumores Neuroendócrinos/radioterapia , Octreotida/análogos & derivados , Compostos Organometálicos/uso terapêutico , Humanos , Octreotida/uso terapêutico , Somatostatina/metabolismo
17.
Eur J Endocrinol ; 181(1): 45-53, 2019 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-31067510

RESUMO

Objectives: Inoperable or metastatic paragangliomas (PGLs) and malignant pheochromocytomas (PCCs) are rare tumours with limited options for systemic treatment. Aim of this study was to assess the safety and efficacy of the radiolabelled somatostatin analogue (177LutetiumDOTA0-Tyr3)octreotate (177Lu-DOTATATE) for the treatment of PGLs and PCCs. Methods: Patients with histologically proven inoperable or malignant PGLs and PCCs treated with 177Lu-DOTATATE at our centre were retrospectively analysed. Patients were treated with up to four cycles of 177Lu-DOTATATE with an intended dose of 7.4 Gb per cycle. Response was assessed with use of RECIST 1.1. Results: Thirty patients were included: 17 with parasympathetic, 10 with sympathetic PGLs and 3 with PCCs. Grade 3/4 subacute haematotoxicity occurred in 6 (20%) of patients. A reversible subacute adverse event due to cardiac failure following possible catecholamine release occurred in two patients. Best tumour response was partial response in 7 (23%) and stable disease in 20 (67%), whereas 3 (10%) patients had progressive disease. In 20 patients with baseline disease progression, tumour control was observed in 17 (85%); the median progression-free survival was 91 months in patients with parasympathetic PGLs, 13 months in patients with sympathetic PGLs and 10 months in patients with metastatic PCCs. Conclusion: This study suggests that PRRT with 177Lu-DOTATATE is a safe and effective treatment option for patients with inoperable or malignant PGL and PCC.


Assuntos
Neoplasias das Glândulas Suprarrenais/radioterapia , Octreotida/análogos & derivados , Compostos Organometálicos/uso terapêutico , Paraganglioma/radioterapia , Feocromocitoma/radioterapia , Radioisótopos/uso terapêutico , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Metástase Neoplásica , Octreotida/uso terapêutico , Doses de Radiação , Receptores de Peptídeos/efeitos da radiação , Estudos Retrospectivos , Resultado do Tratamento
18.
Ann Endocrinol (Paris) ; 80(3): 166-171, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-31053248

RESUMO

Neuroendocrine tumors (NET) represent a heterogeneous group of tumors originating from cells of neuroendocrine origin, which express somatostatin receptors (SSTR). This property allowed the successful development of radionuclides for diagnostic and peptide radionuclide radiation therapy (PRRT). This is the paradigm for the theragnostic concept in NET personalized medicine. The only phase III study to date (NETTER-1) clearly demonstrated the ability of 177Lutetium-based PRRT to improve progression-free survival in advanced intestinal NETs. In clinical practice, the indications are limited to G1-G2 well-differentiated NETs with high expression of SSTR. NETs with a low tumor burden and slow progression are probably the optimal indication. This treatment is now available in France. However, its precise position in the treatment algorithm remains to be explored. We provide an overview of receptor radionuclide utilization and mechanism in diagnostic and pretherapeutic imaging and we focus on PRRT for endocrine tumors.


Assuntos
Tumores Neuroendócrinos/diagnóstico por imagem , Tumores Neuroendócrinos/radioterapia , Receptores de Somatostatina/análise , Ensaios Clínicos Fase III como Assunto , França , Humanos , Lutécio/uso terapêutico , Octreotida/análogos & derivados , Octreotida/uso terapêutico , Compostos Organometálicos/uso terapêutico , Tomografia por Emissão de Pósitrons/métodos , Medicina de Precisão/métodos , Radioisótopos/uso terapêutico , Compostos Radiofarmacêuticos , Radioterapia/métodos , Receptores de Somatostatina/antagonistas & inibidores
19.
Mol Med Rep ; 19(6): 5142-5152, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-31059081

RESUMO

The purpose of the present study was to investigate the effect of carbon monoxide (CO) released from CO­releasing molecule 2 (CORM­2) on mice with acute pancreatitis (AP). To perform the investigation, a mouse AP model was established using caerulein. The mice were treated with or without CORM­2. The survival rate of the mice in the different groups was analyzed, and serum amylase and lipase levels were measured to assess the degree of pancreatic injury. The severity of AP was also evaluated by histological examination, and histopathological scoring of the pancreatic damage was performed. Pancreatic cell apoptosis was analyzed using a terminal deoxynucleotidyl­transferase­mediated dUTP nick end labelling assay. The function of the lung and liver was also assessed in the present study. Furthermore, the role of CORM­2 on oxidative stress, intercellular adhesion molecule 1 (ICAM­1) and vascular cell adhesion molecule 1 (VCAM­1) expression, pro­inflammatory cytokine production, and nuclear factor (NF)­κB activation in the pancreas of AP mice was determined. The results demonstrated that CORM­2 reduced the mortality, pancreatic damage, and lung and liver injury of AP mice. CORM­2 administration also reduced systemic and localized inflammatory cell factors. Furthermore, treatment with CORM­2 inhibited the expression of ICAM­1 and VCAM­1, and the activation of NF­κB and phosphorylated inhibitor of NF­κB subunit α, in the pancreas of AP mice. These results indicated that CO released from CORM­2 exerted protective effects on AP mice, and the beneficial effects were likely due to inhibition of NF­κB pathway activation.


Assuntos
Monóxido de Carbono/metabolismo , Compostos Organometálicos/farmacologia , Pancreatite/prevenção & controle , Doença Aguda , Amilases/sangue , Animais , Ceruletídeo/toxicidade , Citocinas/metabolismo , Modelos Animais de Doenças , Molécula 1 de Adesão Intercelular/metabolismo , Lipase/sangue , Pulmão/metabolismo , Pulmão/patologia , Masculino , Malondialdeído/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , NF-kappa B/metabolismo , Compostos Organometálicos/química , Compostos Organometálicos/uso terapêutico , Estresse Oxidativo/efeitos dos fármacos , Pâncreas/metabolismo , Pâncreas/patologia , Pancreatite/induzido quimicamente , Pancreatite/patologia , Peroxidase/metabolismo
20.
Artigo em Inglês | MEDLINE | ID: mdl-31084597

RESUMO

BACKGROUND: Travelers' diarrhea is the most common travel-related malady. It affects millions of international travelers to developing countries annually and can significantly disrupt travel plans. OBJECTIVE: To provide an update on the evaluation, diagnosis, treatment, and prevention of traveler's diarrhea. METHODS: A PubMed search was completed in Clinical Queries using the key term "traveler's diarrhea". The search strategy included meta-analyses, randomized controlled trials, clinical trials, observational studies, and reviews. The search was restricted to English literature. Patents were searched using the key term "traveler's diarrhea" from www.freepatentsonline.com. RESULTS: Between 10% and 40% of travelers develop diarrhea. The attack rate is highest for travelers from a developed country who visit a developing country. Children are at particular risk. Travelers' diarrhea is usually acquired through ingestion of food and water contaminated by feces. Most cases are due to a bacterial pathogen, commonly, Escherichia coli, and occur within the first few days after arrival in a foreign country. Dehydration is the most common complication. Pretravel education on hygiene and on the safe selection of food items is important in minimizing episodes. For mild travelers' diarrhea, the use of antibiotic is not recommended. The use of bismuth subsalicylate or loperamide may be considered. For moderate travelers' diarrhea, antibiotics such as fluoroquinolones, azithromycin, and rifaximin may be used. Loperamide may be considered as monotherapy or adjunctive therapy. For severe travelers' diarrhea, antibiotics such as azithromycin, fluoroquinolones, and rifaximin should be used. Azithromycin can be used even for the treatment of dysentery whereas fluoroquinolones and rifaximin cannot be used for such purpose. Recent patents related to the management of travelers' diarrhea are discussed. CONCLUSION: Although travelers' diarrhea is usually self-limited, many travelers prefer expedient relief of diarrhea, especially when they are traveling for extended periods by air or ground. Judicious use of an antimotility agent and antimicrobial therapy reduces the duration and severity of diarrhea.


Assuntos
Antibacterianos/uso terapêutico , Azitromicina/uso terapêutico , Bismuto/uso terapêutico , Disenteria/tratamento farmacológico , Infecções por Escherichia coli/tratamento farmacológico , Escherichia coli/fisiologia , Loperamida/uso terapêutico , Compostos Organometálicos/uso terapêutico , Salicilatos/uso terapêutico , Desidratação , Países em Desenvolvimento , Fluoroquinolonas/uso terapêutico , Contaminação de Alimentos , Conhecimentos, Atitudes e Prática em Saúde , Humanos , Educação de Pacientes como Assunto
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA